Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of 2025 ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

SLOWLY lifting her head off her sweat-drenched pillow, Aisleyne Horgan-Wallace vomits into the sick bucket next to her bed. ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.